Registry update — unassessed
Aging Mammary Stem Cells and Breast Cancer Prevention
Trial registry update: TERMINATED. Results are posted in the registry; assessment pending.
OTHERNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 5, 2023 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- This was not a clinical trial in living subjects, so it cannot establish whether rapamycin prevents breast cancer in humans or provides clinical benefit.
- The sample size was not reported, preventing assessment of statistical power or generalizability.
- The specific effect sizes were not reported, limiting ability to judge the magnitude of the reduction in malignant markers or aberrant cells.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- Surgical specimens (breast tissue)
- Primary outcome
- Reduction in malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number
- Effect size
- —
- Significance
- Not reported
- Journal
- LuZhe Sun
- Published
- Dec 5, 2023
Sources
Primary source
- LuZhe Sun ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Aging Mammary Stem Cells and Breast Cancer Prevention
To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.